About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Friday, June 30th, 2017

The QualityStocks
Daily Stock List


GEX Management, Inc. (GXXM)

OTC Markets and MarketWatch reported on GEX Management, Inc. (GXXM), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

GEX Management, Inc. is a licensed Professional Employer Organization (PEO) and a Professional Services Company. It provides complete back office services to its clients in a host of industries. GEX Management’s shares trade on the OTC Markets Group’s OTCQB. The Company has its headquarters in Dallas, Texas.

GEX Management’s services include HR (Human Resources), Payroll, Risk & Compliance Management, Digital Marketing, IT (Information Technology), Executive Consulting, and Accounting/Bookkeeping. The Company utilizes specially designed technology and a team of professionally trained staff to give clients support and accountability. It gives its clients access to technology and systems to set them up for success.

As a PEO, GEX Management provides HR services for its clients, including the payment of wages and taxes, and assisting with state and federal rules and regulation compliance. The Company also provides basic bookkeeping services to its clients. This includes Accounts Payable (A/P); Accounts Receivable (A/R); Accounting Manual and Policy Review; Full Service Accounting Services (Bookkeeping); Paperless Workflow System Implementation; and Document Retention. Its staff can perform cash-based or accrual accounting.

Last week, GEX Management announced that it engaged NMS Capital Advisors, LLC as its financial advisor to explore future growth opportunities for the Company by way of the capital markets and other strategic initiatives.  With this Agreement, NMS Capital will provide investment banking, financial advisory, and broker-dealer services to GEX Management. 

GEX Management announced this week that its Chief Operating Officer (COO), Mrs. Chelsea Christopherson, published an article in Forbes entitled, “How Leaders and Managers Unknowingly Suppress Their Team Members.”  Mrs. Christopherson discusses her personal experiences, and also different situations she has witnessed in which managers suppress, albeit sometimes inadvertently, their own team members.

She details these instances in this article. She provides suggestions about how managers can avoid these common missteps, which can stifle a project, or even lead to employee morale issues. Mrs. Christopherson is one of the youngest women to be an Officer and Director of a public company. 

GEX Management, Inc. (GXXM), closed Friday's trading session at $11.46, up 27.33%, on 1,582 volume with 17 trades. The average volume for the last 60 days is 188 and the stock's 52-week low/high is $1.86/$11.25.

Freedom Leaf, Inc. (FRLF)

Promotion Stock Secrets, CFN Media Group, SmallCapVoice, and StocksToBuyNow reported on Freedom Leaf, Inc. (FRLF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Listed on the OTCQB, Freedom Leaf, Inc. (The Marijuana Legalization Company™) is a foremost go-to resource in the cannabis, medical marijuana, and industrial hemp industry. The Company engages in mergers and acquisitions (M&A’s) in the marijuana industry. This includes incubation/acceleration and spin offs of new marijuana/hemp related companies. The Company does not handle, grow, sell, or disperse marijuana. Freedom Leaf is based in Las Vegas, Nevada.

Freedom Leaf targets acquisitions of high growth and niche companies. Its business strategy is to identify select technology companies and companies that are involved in cannabis and industrial hemp genetics, intellectual property (IP), bioscience, nutraceutical and pharmaceutical product development.

The Company’s flagship publication is Freedom Leaf Magazine, The Good News in Marijuana Reform. Freedom Leaf produces a portfolio of news, print, and digital multi-media verticals, websites, and web advertising, for the ever-changing and developing cannabis, medical marijuana, and industrial hemp industry.

The content Freedom Leaf produces and curates primarily attracts industry professionals, such as lawyers, legislators, activists, entrepreneurs, as well as people active in the business of cannabis and industrial hemp. The Freedom Leaf enterprise has become a leader in media production and distribution for the cannabis/hemp industry.

As of January 2017, Freedom Leaf has now published and circulated 22 editions and hundreds of thousands of copies of its magazine in 36 states, plus the District of Columbia and Puerto Rico. Freedom Leaf magazine provides activists, consumers, patients, and entrepreneurs a reliable means to stay well-informed of the latest marijuana-related information, innovations, and legislation.

At the beginning of June, Freedom Leaf announced that it acquired LaMarihuana.com, which is the Spanish Speaking community's top cannabis website. LaMarihuana (established in 2001) presently has greater than 1.6 million page visits each month.

In addition, as part of this acquisition, Freedom Leaf acquired www.Marihuana-Medicinal.com. This is the largest Medical Cannabis information website in Spanish with more than 122,000 page visits per month.

This week, Freedom Leaf announced that it signed a Letter of Intent (LOI) with the owners of Green Market Europe S. L. (GME) to acquire all of the shares of the Company. This acquisition includes more than 60,000 square feet of operational greenhouse, including more than 20,000 square feet with an automated light deprivation system to stimulate flowering year-round, plus greater than 200 acres of outdoor production. Greenhouse and outdoor production can be increased nearby.

Mr. Clifford J. Perry, Freedom Leaf Co-Founder and Chief Executive Officer, said, "With this transformative acquisition Freedom Leaf has become a major participant not only in the booming CBD (cannabidiol) industry, but in many other aspects of the global hemp industry. Current product development projects include research into rare cannabinoids, CBD drinks, phytocannabinoid oil, hemp seed oil, hemp fabric for footwear and furniture, etc..."

Freedom Leaf, Inc. (FRLF), closed Friday's trading session at $0.05, down 0.99%, on 133,843 volume with 21 trades. The average volume for the last 60 days is 93,906 and the stock's 52-week low/high is $0.0288/$0.31.

CLS Holdings USA, Inc. (CLSH)

MoneyTV, Stock Commander, Equity Observer, Value Penny Stocks, eliteotc, SMS Penny Picks, Wall Street Beauties, WINNINGOTC, SmallCapAllStars, TryBestPennyStocks.biz, HotStockProfits, Beacon Equity Research, InvestorSoup, Penny Stock Craze, Penny Stocks Finder, Stock Preacher, SuperStockTips, Fortune Stock Alerts, Penny Stock Professor, PennyPickAlerts and Traders350 reported previously on CLS Holdings USA, Inc. (CLSH), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

CLS Holdings USA, Inc. is a development stage diversified cannabis company. CLS stands for "Cannabis Life Sciences," in recognition of its patent pending proprietary method of extracting varied cannabinoids from the marijuana plant and converting them into a higher quality and quantity of products. CLS Holdings USA specializes in the extraction and conversion of cannabinoids. The Company is based in Boulder, Colorado.

CLS Holdings USA’s mission is to be the industry leader in the extraction, conversion and marketing of cannabinoid oils, wax, edibles, and shatter through taking advantage of its proprietary extraction methods and conversion processes. Its business model includes licensing operations, processing revenue, processing facilities, sale of products, brand creation, and consulting services.

CLS Labs took its initial step toward commercializing its proprietary methods and processes through entering into an arrangement in Colorado on April 17, 2015. It entered into an arrangement by way of CLS Labs Colorado to, among other things, license its proprietary technology, methods and processes to PRH in exchange for a fee; and build a processing facility and lease such facility, including equipment, to PRH.

CLS will agree to build out a processing facility and then lease the facility and equipment to the client for what will usually be a 10-year term. The client will be required to enter into an agreement of equal length to license CLS’s proprietary technology, methods, and processes exclusively for use in the processing facility.

The Company’s plan is to monetize the extraction method and generate revenues via the licensing of its proprietary methods and processes to others, as in the Colorado Arrangement, the processing of cannabis for others, and the purchase of cannabis and the processing and sale of cannabis-related products.

CLS Holdings USA’s aim is to enter into arrangements with cannabis growers; CLS will process their cannabis for a fee. Under such arrangements, growers will deliver cannabis plants to one of CLS’s facilities for processing. CLS Holdings will then apply its proprietary extraction and conversion technology to produce cannabinoid concentrates, which may be delivered to the grower in bulk form or, for an additional fee, in individually-labeled retail-ready packages of oils, edibles, wax or shatter.

Today, CLS Holdings USA announced that it entered into a non-binding Letter of Intent (LOI) with privately owned Pure Harvest Cannabis Producers, Inc. of Las Vegas, Nevada. Pure Harvest is a science-based medical cannabis enterprise led by a team of respected veterans in business and in the cannabis industry. Its plan is to become a licensed vertically integrated cannabis business involved in all facets of the cannabis cycle. This includes plant science, cultivation, production, medical and recreational dispensaries, and delivery.

Upon closing, the expectation is that CLS Holdings will relocate to Las Vegas and change its name to "Pure Harvest Cannabis Group, Inc." The LOI is subject to several conditions and contingencies. This includes the due diligence to be performed by both parties.

CLS Holdings USA, Inc. (CLSH), closed Friday's trading session at $0.2999, up 199.90%, on 582,002 volume with 179 trades. The average volume for the last 60 days is 20,179 and the stock's 52-week low/high is $0.0247/$1.83.

Semler Scientific, Inc. (SMLR)

Marketbeat, Wall Street Resources, Money Morning, and Barchart reported earlier on Semler Scientific, Inc. (SMLR), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Semler Scientific, Inc. is a medical risk-assessment company. Its corporate mission is to develop, manufacture, and market patented products, which identify the risk profile of medical patients to permit healthcare providers to capture full reimbursement potential for their services. Semler Scientific provides technology and software solutions to improve the clinical effectiveness of healthcare insurers and physician groups. Semler Scientific is based in Portland, Oregon.

The Company’s aim is to develop, manufacture, and market inventive proprietary products and services, which assist its customers in evaluating and treating chronic diseases.  Its diagnostic and testing products and services assist in guiding patient care. They close the gap between the cost of care and compensation for care. Fundamentally, Semler Scientific provides diagnostic and testing services to the U.S.’s top health plans and providers.

Semler manufactures the QuantaFlo™ system for Vascular Disease testing. The QuantaFlo™ system is very suitable for use in primary care offices, specialty practices, health fairs, or during home assessments.

The QuantaFlo™ PAD test delivers fast, accurate results in about five minutes at the point of care. In March of 2015, Semler received Food and Drug Administration (FDA) 510(k) clearance for the next generation version of QuantaFlo™, which commercially launched in August of 2015.

In addition, Semler Scientific has its WellChec™ service. WellChec™ is a service providing turn-key assessment testing across the U.S. for an assortment of conditions. It provides turnkey solutions for administering important clinical tests that can impact HCC classifications, CPT coding, HEDIS and Quality Measures. The Company launched its multi-test service platform, WellChec™ in April of 2015.

In November 2016, Semler Scientific announced that it ranked No. 176 on Deloitte's Technology Fast 500™. This a ranking of the 500 fastest growing technology, life sciences, and energy technology companies in North America. This ranking made Semler the 9th fastest growing company in the Medical Device category according to Deloitte.

The Technology Fast 500™ award winners were chosen based on percentage fiscal year revenue growth from 2012 to 2015. Over this period, Semler Scientific's revenue growth was 484 percent.

Recently, Semler Scientific reported financial results for Q1 ended March 31, 2017. For the three months ended March 31, 2017, versus the corresponding period of 2016, the Company had Revenue of $2,055,000, an increase of $554,000, versus $1,501,000. It had a Net Loss of $871,000, or $0.17 per share, a decrease of $135,000, versus a Net Loss of $1,006,000, or $0.20 per share.

Semler Scientific, Inc. (SMLR), closed Friday's trading session at $3.10, up 3.33%, on 709 volume with 5 trades. The average volume for the last 60 days is 2,142 and the stock's 52-week low/high is $1.28/$3.50.

CTD Holdings, Inc. (CTDH)

Wall Street Resources, Nebula Stocks, Greenbackers, and HotStockChat reported earlier on CTD Holdings, Inc. (CTDH), and we are highlighting the Company today, here at the QualityStocks Daily Newsletter.

OTCQB-listed, CTD Holdings, Inc. is a biotechnology company developing cyclodextrin-based products for the treatment of disease. This includes Trappsol® Cyclo™. The Company’s other divisions distribute and manufacture the trademarked Trappsol® and Aquaplex® cyclodextrins, cyclodextrin derivatives, and cyclodextrin complexes for biotechnology and life science companies involved in the research, pharmaceutical, medical device, cosmetics, and nutrition markets. CTD Holdings has its corporate headquarters in Alachua, Florida.

Its Trappsol® Cyclo™ is an orphan drug designated product. It is for the treatment of Niemann-Pick Type C (NPC). This is a rare and frequently fatal genetic disease in young children that also results in major health impairment for affected adults. NPC impacts the brain, lung, liver, spleen, and other organs. Additional indications for the active ingredient in Trappsol® Cyclo™ are in development. This includes peripheral artery disease, diabetic nephropathy, as well as acute viral infections.

Furthermore, the Company’s other divisions operate the world's only cGMP pulse drying facility to produce UltraPure™ cyclodextrin derivatives and pharmaceutical grade Aquaplex® cyclodextrin complexes. Also, they supply cyclodextrins to biotechnology and life science researchers around the world from the world's largest catalog of cyclodextrins.

The UK Medicines and Healthcare Products Agency (MHRA) approved CTD Holdings’ Clinical Trial Application (CTA) for its orphan drug product, Trappsol® Cyclo™, in the treatment of Niemann-Pick Type C (NPC) disease. The CTA described the Company’s Phase I/II clinical plans to administer Trappsol® Cyclo™ intravenously to patients in the UK as young as two years old and into adulthood. The product has Orphan Drug Designation in the European Union and the U.S.

CTD Holdings filed a CTA with Italy's drug regulator, the Agenzia Italiana del Farmaco (AIFA) to conduct a Phase I/II clinical trial in Italy of CTD's Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C.

Last week, CTD Holdings announced that it enrolled the first patient in its European Phase I/II clinical trial evaluating the intravenous administration of Trappsol® Cyclo™ in patients with Niemann-Pick Disease Type C (NPC). The first patient was enrolled at Salford NHS Trust UK by Dr. Reena Sharma, Consultant for Adult Metabolic Medicine and Honorary Senior Lecturer at the Mark Holland Metabolic Unit. Additionally, Dr. Sharma is the Coordinating Investigator for the Phase I/II trial in Europe.

This week, CTD Holdings announced that it shipped 660 additional vials of its Trappsol® Cyclo™ product to the government of Brazil under a business relationship now in its seventh year. It has an exclusive supplier agreement with the government of Brazil and distributes to the nation via its exclusive distribution partner UnoHealthcare of Miami, Florida.

CTD Holdings, Inc. (CTDH), closed Friday's trading session at $0.49, up 32.08%, on 13,430 volume with 7 trades. The average volume for the last 60 days is 10,396 and the stock's 52-week low/high is $0.33/$0.80.


The QualityStocks
Company Corner


Players Network, Inc. (PNTV)

The QualityStocks Daily Newsletter would like to spotlight Players Network, Inc. (PNTV). Today, Players Network, Inc. closed trading at $0.16, up 28.51%, on 19,765,211 volume with 1,654 trades. The stock’s average daily volume over the past 60 days is 3,057,817, and its 52-week low/high is $0.0023/$0.1315.

Players Network, Inc. today announces the availability of its Green Leaf Farms rosin products at the Pisos Dispensary, and its celebratory initiatives as the State of Nevada commences legal recreational marijuana use. The State of Nevada -- especially the City of Las Vegas -- is emerging as the next "Amsterdam," and is expected to become the largest recreational marijuana market in the world. To ring in this historical occasion, Weed TV will cover, as part of its upcoming "High Stakes" television series, a special event from Pisos Dispensary. For maximum exposure, Weed TV will cover the event via live video broadcast and social media updates and livestreams.

Players Network, Inc. (PNTV) is a diversified holding company operating in marijuana and media. PNTV owns 86% of Green Leaf Farms Holdings, LLC (Green Leaf Farms) which has Nevada state-issued cultivation and production license(s). The cultivation license enables Green Leaf Farms to grow marijuana and the production license enables them to create extracts which are used for cartridges, oils and edibles. WeedTV.com is a wholly owned subsidiary which is developing the ultimate resource for the marijuana lifestyle. PNTV has been a fully reporting, publicly traded company since 1998.

Green Leaf Farms Holdings, LLC (Green Leaf)

Green Leaf produces medical and recreational cannabis products. Revenues are generated by selling their cannabis products to licensed dispensaries throughout Nevada.

Their mission is to produce the highest quality and safest pharmaceutical-grade cannabis to all levels of consumers. They utilize the most efficient cultivation methods in order to lower expenses for consumers and to maximize returns for investors.

They are a privately held company with a unique business model as they are one of only a few companies who have been granted 2 (two) Medical Marijuana Establishment (MME) licenses in Nevada; Cultivation and Production.

Their Cultivation License enables them to grow cannabis which will produce flower. Their Production License enables them to process flower (cannabis) and cannabis byproducts into extremely pure concentrates, extracts, and oils which are used in medicine, cartridges and edibles. Green Leaf has both acquired and developed proprietary cannabis strains and will continue to be committed to cannabis research and development.

Green Leaf is located in North Las Vegas, Nevada on 2.3 acres in a state-of-the-art 26,000 sq. ft. facility. They have a seasoned team of professional growers and operators to manage the facility with proven best practices to ensure they have the highest quality products available.


WeedTV.Com is a niche social network and lifestyle channel destination for the marijuana industry. They are developing the "go-to" source for information, entertainment, products and services for people who relate to the marijuana lifestyle and an active social community. WeedTV.com features daily stories sourced by WeedTV.com correspondents and contributors from around the world.

Programming includes, political news, business news on the industry, financial analysis from industry experts, growing tips, cooking tips, the "Weed101" section, medical applications/issues, lifestyle features, and entertainment specials.

WeedTV.com's first original series is titled "High Stakes." High Stakes was developed by Michael Berk, the company's Chief Creative Officer and creator of one of the most popular cable series of all time, Baywatch. High Stakes is docu-series that follows the team at Green Leaf Farms as they build their facility and launch their marijuana business.

By leveraging media, WeedTV.com builds long-term brand equity and connects consumers to businesses. This is accomplished through fresh and relevant content such as professionally produced branded television segments, user-generated videos, blogs, editorials, tweets (twitter), photos, special offers, events and custom-designed contests to engage both consumers and businesses with their brands and services.

Marijuana and Media Strategy

While developing WeedTV.com, the PNTV team realized they could implement a vertical strategy to utilize their media platform (WeedTV.com) to drive business and awareness to their cannabis products (Green Leaf Farms). Through the audience and reach of WeedTV.com, they will build brand value and cross market their own marijuana products, as well as generate revenues by marketing other companies' products and services. Disclaimer

Players Network, Inc. Company Blog

Players Network, Inc. News:

Player's Network's Weed TV to Live Broadcast First Recreational Marijuana Transaction at Pisos Dispensary in Las Vegas

Player's Network, Inc. Appoints Geoffrey Lawrence, Nevada Assistant State Controller, as Chief Financial Officer, Chief Compliance Officer

Player's Network, Inc. CEO Featured on MoneyTV with Donald Baillargeon, 6/2

Kootenay Zinc Corp. (CSE:ZNK) (OTCQB:KTNNF)

The QualityStocks Daily Newsletter would like to spotlight Kootenay Zinc Corp. (KTNNF). Today, Kootenay Zinc Corp. closed trading at $0.1208, up 26.76%, on 39,500 volume with 17 trades. The stock’s average daily volume over the past 60 days is 98,117, and its 52-week low/high is $0.081/$0.59.

Kootenay Zinc Corp. (KTNNF) is a mineral exploration and development company focused on discovering large-scale sedimentary-exhalative ("SEDEX") zinc deposits. Based in Vancouver, British Columbia, the company is ideally positioned near its primary target, the Sully Property, located 18 miles east of the world-class Sullivan Mine.

Of the 22 raw materials tracked by the Bloomberg Commodity Index, zinc was the best-performing base metal in 2016. Based on a widening global supply deficit, outlook for the commodity remains strong. As the most closely tied base metal to the Chinese economy, zinc demand and prices are expected to rise well into the year 2020, putting increased pressure on zinc supply.

For 2017, Goldman Sachs has predicted a 360,000 ton shortage of zinc, along with a subsequent rise in zinc prices to $2,500 per metric ton in the first half of the year. Zinc continues to make history in the metals exchange, driving significant interest in the market amid supply constraints in concentrates and refined metal drive prices.

Ready to claim its share of the market, Kootenay Zinc is focused on its Sully Property. It comprises 1,375 hectares and overlies rocks of similar age and origin as those which host the legendary Sullivan deposit. The Sullivan mine was discovered in 1892, and is known to be one of the world's largest SEDEX deposits. Over its 100-year lifetime, Sullivan produced approximately 150 million tonnes of ore, including approximately 300 million ounces of silver, 8 million tonnes of zinc and 8 million tonnes of lead.

Notably, geophysical data suggests that Kootenay Zinc's Sully project and Sullivan share many geological features:

  • Strata at Sully are in the same sedimentary basin as the Sullivan mine
  • The exact stratigraphic time horizon at which Sullivan formed is present at Sully
  • Filtered AeroMag anomalies coincident with Sullivan Time at Sully appear similar to Sullivan
  • Gravity anomaly at Sully indicates excess mass of comparable magnitude to Sullivan
  • Pb-Zn is present as traces in outcrop, drill core and in a soil geochemical anomaly

The squeeze in zinc supplies particularly affects China, which is both the world's largest zinc consumer and its largest producer, with 4.9 million tons of output in 2015. Chinese manufacturers are now being forced to import zinc for use in cars, household appliances, paints, rubber products and smartphones.

Zinc's rally shows no sign of slowing down in the near future, and companies that currently occupy stake in a zinc deposit find themselves in an enviable position over miners rushing to find new reserves. With its Sully Project, Kootenay Zinc could be on track to capture its share of the market, guided by a management team of mining directors and executives that currently lead some of the world's best mining companies and have been involved in world-class discoveries which sold for billions of dollars. The company's technical team includes industry experts that have worked on mega-mining projects, including the Sullivan and Voisey Bay projects. Disclaimer

Kootenay Zinc Corp. Company Blog

Kootenay Zinc Corp. News:

Sully Project - E3 Target Drilling Underway

Kootenay Zinc Corp.: Sully Project Exploration Update

NetworkNewsWire Releases Exclusive Audio Interview with Kootenay Zinc Corp. (KTNNF)

InMed Pharmaceuticals, Inc. (IMLFF)

The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals, Inc. (IMLFF). Today, InMed Pharmaceuticals, Inc. closed trading at $0.256, up 2.40%, on 107,678 volume with 82 trades. The stock’s average daily volume over the past 60 days is 760,791, and its 52-week low/high is $0.05/$0.72.

InMed Pharmaceuticals, Inc. (IMLFF) is a preclinical-stage biopharmaceutical company specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids. Utilizing its proprietary bioinformatics assessment tool, InMed aims to identify bioactive compounds found within the cannabis plant that have the potential to offer optimized therapeutic benefit while demonstrating limited adverse effects. This assessment tool, in combination with the company’s cannabinoid biosynthesis technology and drug development pipeline, serves as InMed’s fundamental value driver.

Bioinformatics is a proprietary, computer-based program designed to assist in the identification of novel cannabinoids using comprehensive algorithms to integrate data from numerous bioinformatics databases, as well as a database on the structure of currently approved pharmaceutical products and an extensive database on over 90 individual cannabinoid drugs found in cannabis. This extensive collection of data is derived from both public and propriety-based sources. Leveraging this tool, the company aims to create associations between approved pharmaceuticals and cannabinoids with similar structures in order to identify active cannabinoids that have the potential to treat specific diseases. Per InMed’s website, this type of bioinformatics assessment represents “significant promise for future drug discovery, as it integrates many data sets and builds holistic models to approach a specific disease.”

After discovering these promising active cannabinoids, InMed moves to test and confirm their activity in biological systems through in vitro and in vivo experimentation. It is at this stage of development that the company’s proprietary biosynthesis process of cannabinoid manufacturing will be most promising. InMed is currently developing a robust, high-yield biosynthesis process for manufacturing all 90+ naturally-occurring cannabinoids. By modifying the agriculture-based formula for harvesting cannabinoids, InMed aims to combine the inherent safety and known efficacy of the natural drug structure with the convenience, control and quality of 21st Century laboratory-based manufacturing processes.

The company’s pipeline currently includes two drug candidates in preclinical development, including INM-750 for the treatment of epidermolysis bullosa (EB) and INM-085 for the treatment of glaucoma. Referred to by the Dystrophic Epidermolysis Bullosa Research Association of America as “The Worst Disease You’ve Never Heard Of,” EB is a rare genetic connective tissue disorder that affects roughly one out of every 20,000 births in the United States. The condition currently has no approved treatment or cure. Through the development of INM-750, InMed is attempting to address this significant unmet medical need. The drug candidate replaces missing keratins in the skin with specially selected cannabinoids in an effort to modulate the painful manifestations of EB.

INM-085, InMed’s second development candidate, is formulated to reduce the elevated intra-ocular pressure that is often associated with glaucoma. Additionally, the cannabinoids utilized in INM-085 are expected to provide neuroprotection for the retinal ganglion cells and other optic nerve tissues following topical administration. Although it is still in preclinical development, INM-085 targets a sizable market. According to the Glaucoma Research Foundation, glaucoma is a leading cause of blindness with no approved cure. The National Institutes of Health estimates that more than 3 million Americans currently have glaucoma, and more than 120,000 have been blinded by the disease.

InMed is focused on progressing toward validation of its drug candidate selection, using data to secure its patents and developing key disruptive technologies. In 2016, the company was successful in completing financings of $1.9 million. In January 2017, InMed completed a non-brokered private placement of common shares generating aggregate gross proceeds of C$1.5 million, strongly positioning the company to attract the new investment required to fund its aggressive growth strategies in 2017.

The company’s management team has well over a century of combined experience in the biopharmaceutical space. Company CEO Eric Adams has more than 25 years of experience in company and capital formation, global market development, mergers and acquisitions, licensing and corporate governance. During his time as CEO of enGene Inc., he led the gene therapy startup to a position at the head of the industry.

Joining Adams on the InMed management team are Chief Scientific Officer Dr. Sazzan Hossain; Senior Vice President, Clinical and Regulatory Affairs Alexandra D.J. Mancini; SVP, Corporate Strategy & Investor Relations Chris Bogart; and Chief Financial Officer Jeff Charpentier, as well as Chief Medical Officer Dr. Ado Muhammed, MD, DPM, MFPM.

Muhammed, in particular, has an extensive history in the pharmaceutical industry, having previously served as an executive of GW Pharmaceuticals, a global leader in the development of cannabinoid-based medicines. During his time as Associate Medical Director of that company, Muhammed played an instrumental role in the development and FDA approval of one of the first cannabis drugs. This GW Pharmaceuticals development program coincided with a sharp rise in share price from less than $9 in 2013 to more than $129 today, with the company’s current market value totaling more than $2.9 billion. Disclaimer

InMed Pharmaceuticals, Inc. Company Blog

InMed Pharmaceuticals, Inc. News:

InMed Pharma Advances Toward Clinical Trials with CRO Deal -- CFN Media

InMed Announces Agreement to Advance a Topical Formulation of INM-750

InMed Raises $5.75 Million Through Underwritten Financing Including Full Exercise of the Over-Allotment Option

ChineseInvestors.com (CIIX)

The QualityStocks Daily Newsletter would like to spotlight ChineseInvestors.com (CIIX). Today, ChineseInvestors.com closed trading at $0.96, up 2.13%, on 3,828 volume with 18 trades. The stock’s average daily volume over the past 60 days is 56,305 and its 52-week low/high is $0.12/$2.75.

Founded in 1999, ChineseInvestors.com (CIIX) has become a leading financial information website for Chinese-speaking investors in the United States and China. Recognizing unprecedented opportunities in the U.S. cannabis industry, CIIX is also laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products.

Through its primary website, www.ChineseInvestors.com, CIIX offers a variety of investor education products and services, including real-time market commentary, analysis and educational related services in Chinese language character sets; consultative services to smaller private companies considering becoming a public company; and advertising and public relations related support services.

At the center of this initiative is the ChineseInvestors Method, a unique integration of a disciplined investing process, web-based tools, personalized instructions and support. Using this strategy, CIIX provides reliable market information to help investors make informed investment decisions and meet their individualized financial goals.

CIIX is also leveraging its financial expertise to enter into the burgeoning CBD industry, which within a few years has grown from a relatively invisible sector to a billowing market expected to reach $2.1 billion in consumer sales by 2020.

The increasing demand for CBD-based products is a catalyst for innovative business endeavors. To this accord, CIIX has established a three-year development plan to capitalize on the convergence of CBD and the nutrition and health products market in mainland China, where the benefits of CBD oil have not been widely recognized.

Under a wholesale agreement with a reputable CBD health brand, CIIX is launching the world's first online CBD health products store published in the Chinese language. The site, www.ChineseCBDoil.com, caters to a growing number of Chinese people awakening to the numerous health benefits of CBD oil for treatment of a variety of conditions such as anxiety, stress, poor sleep, Alzheimer's disease, and more. CIIX expects to launch this website at the end of January 2017, and plans to sell CBD-infused products via online and in-store.

In conjunction, CIIX's cannabis-focused "Yelp"-style mobile app is in development as a platform for Chinese people to review and discuss various cannabis products. The app will be the first marijuana social media mobile app designed for Chinese-speaking customers worldwide. Disclaimer

ChineseInvestors.com Blog

ChineseInvestors.com News:

CFN Media Interviews ChineseInvestors.com CEO Warren Wang

ChineseInvestors.com, Inc.'s Wholly-owned Foreign Enterprise, CBD Biotechnology Co. Ltd., Will Launch its First Hemp Infused Skin Care Line in China

ChineseInvestors.com, Inc. Launches CBD Biotechnology Inc. in British Columbia, Canada

Algae Dynamics Corp. (ADYNF)

The QualityStocks Daily Newsletter would like to spotlight Algae Dynamics Corp. (ADYNF). Today, Algae Dynamics Corp. closed trading at $0.10, even with yesterday's close, on 14,000 volume with 3 trades. The stock’s average daily volume over the past 60 days is 11,387 and its 52-week low/high is $0.0001/$0.75.

Algae Dynamics Corp. (ADYNF) is focused on developing proprietary research and products involving botanical oils derived from cannabis and algae.

The original core of the company's product development strategy was the extraction of Omega-3 fatty acids from certain strains of algae with high concentrations of DHA to create various nutraceutical products. As a result of the many demonstrated health benefits of other botanical oils, most notably cannabis oil, Algae Dynamics developed a strategy aimed at developing products that combined the health benefits of algae and cannabis oils. Capitalizing on the burgeoning demand for cannabis oil and other smoke-free alternatives to marijuana consumption will help support ongoing initiatives to create and market research-driven product formulations.

Although the company is publicly traded in the U.S., business is conducted in Canada with no exposure to U.S. federal regulation involving cannabis. The Canadian cannabis oil extraction marketplace is projected to grow from C$1 million in 2015 to C$1.7 billion in 2020, which is more than a 1,000-fold increase. With the Government of Canada indicating a target date for full legalization on or before July 2018, numerous opportunities for sales in extracts and oils will open up very soon.

Using Colorado as a comparable example, a study performed by Mackie Research Capital found that 45% of dried marijuana users in the state would eventually convert to marijuana extracts and oils. This is because most consumers taking cannabis for medical purposes are increasingly looking for delivery systems that do not involve smoking marijuana. The market's attractiveness can be further realized when considering that the Canada's licensed producer marketplace is far less competitive with 45 current licensed producers for the whole country vs. 624 licensed cultivators in Colorado.

Collaborating with prominent Canadian universities is a core part of the Algae Dynamics' plan to bolster cannabis extraction expertise, develop premium products and add to its portfolio of intellectual property. Through its agreements with the University of Waterloo and the University of Western Ontario, the company is focusing primarily on the use of extracts from cannabis oil and algae oil in the context of cancer as well as the development of new pharmacotherapies for mental health.

Near-term goals include expanding research and development work with existing and new Canadian universities, securing supply/service agreements with licensed producers, and submitting an application to Health Canada to become a licensed producer of medical marijuana and ultimately have a license to sell products derived from cannabinoids. Algae Dynamics also owns a proprietary technology for the cultivation of low cost, highly pure algae biomass, which will be developed as a vertical integration strategy in the future to support the need to source algae oil for research-driven product formulations. The management team leading these initiatives has nearly a century of beneficial experience spanning from management and process experience to successful fund raising and commercialization.

As part of its key objective to be the #1 research Canadian cannabis oil research-driven product formulator, the company has also formed a strong team of scientific and strategic advisors that complement ongoing R&D relationships and initiatives. Individuals who support the company's initiatives include Dr. Jonathan Blay PhD, FRSB, FIBMS, Csci, CBiol, who performs research and product development on cannabis oil and its constituents in the context of colorectum, pancreas, breast and prostate cancers; and Dr. Steven Laviolette, BSc, PhD, who performs research and product development on cannabis oil and its constituents in the context of depression, post-traumatic stress disorder, anxiety and schizophrenia.

With such a strong foundation laid in the areas being pursued, Algae Dynamics is well positioned to execute on its carefully developed business plan to fast-track to revenue growth while having a longer-term strategy to build a sustainable enterprise-building opportunity in a rapidly expanding market. Disclaimer

Algae Dynamics Corp. Blog

Algae Dynamics Corp. News:

Algae Dynamics Corp. (ADYNF) Engages NetworkNewsWire for Corporate Communications Solutions

Algae Dynamics Corp Announces Engagement of Atlanta-Based Broker Dealer Carter, Terry & Company

Algae Dynamics Corp Announces Memorandum Of Understanding With Bonify for Supply of Cannabis, Oil Extraction and Sales


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters



(CLSH) +199.90%


(EACQW) +143.68%


(AMIN) +42.86%

By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251